NCT03178084View on ClinicalTrials.gov

Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

PHASE3CompletedINTERVENTIONAL
Enrollment

721

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

November 5, 2016

Study Completion Date

March 7, 2017

Conditions
HIV/AIDS
Interventions
DRUG

Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID

maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily

DRUG

Efavirenz QD + Zidovudine/Lamivudine BID

efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)

DRUG

Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD

maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT03178084 - Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio | Biotech Hunter | Biotech Hunter